Skip to the content
  • 719-347-5400
  • info@realmofcaring.org
  • 719-347-5400
  • info@realmofcaring.org
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
Menu
  • Research
    • Observational Research Registry
    • Company Interest
    • Research Library
    • Women’s Veteran Study
  • Resources
    • Client Portal
      • Dosing & Administration
      • Client Education Series
      • Client F.A.Q.
        • Client Additional Questions
      • For Pets
      • Glossary
      • Observational Research Registry
      • Printable Resources
      • Supported Brands
    • Healthcare Portal
      • Dosing & Administration
      • Join Our List of Healthcare Professionals
      • Practitioner Education
    • Find a Provider
      • Locate a Healthcare Professional
      • Medical Cannabis Cards
  • Blog
    • Cannabis Education
    • Client Stories
  • About
    • Who We Are
    • In the News
    • Supported Brands
    • Our Supporters
    • Financials
  • Contact Us
    • Call or Email
    • Request an Appointment
  • Donate
  • Register
  • Login
  • Anandamide (AEA), Cannabinoid receptor/s, Dopamine, insomnia
Loading...

Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats

Abstract   Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are two major constituents of Cannabis sativa. Δ9-THC modulates sleep, but no clear evidence on the role of CBD is available. In order to determine the effects of CBD on sleep, it was administered intracerebroventricular (icv) in a dose of 10 μg/5 μl at the beginning of either the lights-on or the lights-off period. We found that CBD administered during the lights-on period increased wakefulness (W) and decreased rapid eye movement sleep (REMS). No changes on sleep were observed during the dark phase. Icv injections of CBD (10 μg/5 μl) induced an enhancement of c-Fos expression in waking-related brain areas such as hypothalamus...
Read More

Lower circulating endocannabinoid levels in children with autism spectrum disorder

Abstract   Background The endocannabinoid system (ECS) is a major regulator of synaptic plasticity and neuromodulation. Alterations of the ECS have been demonstrated in several animal models of autism spectrum disorder (ASD). In some of these models, activating the ECS rescued the social deficits. Evidence for dysregulations of the ECS in human ASD are emerging, but comprehensive assessments and correlations with disease characteristics have not been reported yet.   Methods Serum levels of the main endocannabinoids, N-arachidonoylethanolamine (AEA or anandamide) and 2-arachidonoylglycerol (2-AG), and their related endogenous compounds, arachidonic acid (AA), N-palmitoylethanolamine (PEA), and N-oleoylethanolamine (OEA), were analyzed by liquid chromatography/tandem mass spectrometry in 93 children with...
Read More

Endocannabinoid system: Role in depression, reward and pain control (Review)

Abstract   Depression and pain co-exist in almost 80% of patients and are associated with impaired health-related quality of life, often contributing to high mortality. However, the majority of patients who suffer from the comorbid depression and pain are not responsive to pharmacological treatments that address either pain or depression, making this comorbidity disorder a heavy burden on patients and society. In ancient times, this depression-pain comorbidity was treated using extracts of the Cannabis sativa plant, known now as marijuana and the mode of action of Δ9-tetrahydrocannabinol, the active cannabinoid ingredient of marijuana, has only recently become known, with the identification of cannabinoid receptor type 1...
Read More

Enhancing Endocannabinoid Control of Stress with Cannabidiol

Abstract   The stress response is a well-defined physiological function activated frequently by life events. However, sometimes the stress response can be inappropriate, excessive, or prolonged; in which case, it can hinder rather than help in coping with the stressor, impair normal functioning, and increase the risk of somatic and mental health disorders. There is a need for a more effective and safe pharmacological treatment that can dampen maladaptive stress responses. The endocannabinoid system is one of the main regulators of the stress response. A basal endocannabinoid tone inhibits the stress response, modulation of this tone permits/curtails an active stress response, and chronic deficiency...
Read More

The Endocannabinoid System of Animals

Our understanding of the Endocannabinoid System of animals, and its ubiquitous presence in nearly all members of Animalia, has opened the door to novel approaches targeting pain management, cancer therapeutics, modulation of neurologic disorders, stress reduction, anxiety management, and inflammatory diseases. Both endogenous and exogenous endocannabinoid-related molecules are able to function as direct ligands or, otherwise, influence the EndoCannabinoid System (ECS). This review article introduces the reader to the ECS in animals, and documents its potential as a source for emerging therapeutics.
Read More

Endocannabinoid Anandamide Mediates the Effect of Skeletal Muscle Sphingomyelins on Human Energy Expenditure

Abstract   Context: Skeletal muscle endocannabinoids and sphingolipids (particularly sphingomyelins) are inversely associated with sleeping energy expenditure (SLEEP) in humans. The endocannabinoid system may increase sphingolipid synthesis via cannabinoid receptor-1.   Objective: To investigate in human skeletal muscle whether endocannabinoids are responsible for the effect of sphingomyelins on SLEEP.   Design: Muscle endocannabinoid [anandamide (AEA), 2-arachidonoylglycerol (2-AG)], endocannabinoid congeners [oleoylethanolamide (OEA), palmitoylethanolamide (PEA)], and sphingomyelin content were measured with liquid chromatography/mass spectrometry. SLEEP was assessed in a whole-room indirect calorimeter. Mediation analyses tested whether the inverse associations between sphingomyelins and SLEEP depended on endocannabinoids and endocannabinoid-related OEA and PEA.   Setting: Inpatient study.   Participants: Fifty-three Native Americans who...
Read More

Fatty acid amide hydrolase is lower in young cannabis users

Abstract   We have recently shown that levels of fatty acid amide hydrolase (FAAH), the enzyme that metabolizes the endocannabinoid anandamide, are lower in the brains of adult cannabis users (CUs) (34 ± 11 years of age), tested during early abstinence. Here, we examine replication of the lower FAAH levels in a separate, younger cohort (23 ± 5 years of age). Eighteen healthy volunteers (HVs) and fourteen CUs underwent a positron emission tomography scan using the FAAH radioligand [11C]CURB. Regional [11C]CURB binding was calculated using an irreversible two-tissue compartment model with a metabolite-corrected arterial plasma input function. The FAAH C385A genetic polymorphism (rs324420) was...
Read More

Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide

Abstract   Mast cells are multifunctional bone marrow-derived cells found in mucosal and connective tissues and in the nervous system, where they play important roles in tissue inflammation and in neuroimmune interactions. Very little is known about endogenous molecules and mechanisms capable of modulating mast cell activation. Palmitoylethanolamide, found in peripheral tissues, has been proposed to behave as a local autacoid capable of downregulating mast cell activation and inflammation. A cognate N-acylamide, anandamide, the ethanolamide of arachidonic acid, occurs in brain and is a candidate endogenous agonist for the central cannabinoid receptor (CB1). As a second cannabinoid receptor (CB2) has been found in peripheral...
Read More

Endocannabinoids as Guardians of Metastasis

Endocannabinoids including anandamide and 2-arachidonoylglycerol are involved in cancer pathophysiology in several ways, including tumor growth and progression, peritumoral inflammation, nausea and cancer pain. Recently we showed that the endocannabinoid profiles are deranged during cancer to an extent that this manifests in alterations of plasma endocannabinoids in cancer patients, which was mimicked by similar changes in rodent models of local and metastatic cancer. The present topical review summarizes the complexity of endocannabinoid signaling in the context of tumor growth and metastasis.
Read More

Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation

A few years ago the endocannabinoid system has been recognized as a major neuromodulatory system whose main functions are to exert and maintain the body homeostasis. Several different endocannabinoids are synthesized in a broad class of cell types, including those in the brain and the immune system; they bind to cannabinoid G-protein-coupled receptors, having profound effects on a variety of behavioral, neuroendocrine and autonomic functions. The coordinated neural, immune, behavioral and endocrine responses to inflammation are orchestrated to provide an important defense against infections and help homeostasis restoration in the body. These responses are executed and controlled mainly by the hypothalamic-pituitary adrenal axis. Also,...
Read More
1 2 3 … 5 Next »

REGISTER WITH RoC TODAY!

Realm of Caring focuses on research, education, building community, and improving quality of life. We are an educational resource for consumers, physicians, scientists, governments and the media.
Register now
  • PO Box 15224, Colorado Springs, CO 80935
  • 719-347-5400
  • info@realmofcaring.org

Copyright © 2023 / Realm of Caring Foundation, Inc

  • Privacy
  • Disclaimer